Cells Gone Wild: Creating Vaccines that Target Cancer
Source: Severine Kirchner, The Penny Sleuth  (3/27/13)
"Now that cancer vaccines have entered phase 3 clinical trials, the possibility that we might one day be able to get our cancer shot together with our flu shot seems much more plausible." More >

Solving the R&D Investment Dilemma with Project Funding: Mark Kessel
Source: George S. Mack of The Life Sciences Report  (3/21/13)
Big pharma knows how to market products. But has it lost a step on the drug development side? Is there a better way to incentivize drug development and make money at it? Mark Kessel, co-founder and partner at private equity firm Symphony Capital LLC, has developed an investment technique that funds promising biotech companies without exposure to all the losses built into a startup model. In this interview with The Life Sciences Report, Kessel talks about his method and how it has worked with specific biotech companies. More >

This Biotech Patent Leader Generates an 8.3% Dividend Yield
Source: Michael Robinson, Money Morning  (3/19/13)
"A biotech, you see, is no different than any other kind of high-tech firm: If it has enough patents, it can use them as a cash-generating machine." More >

Biotech Sector Analysis: March Madness
Source: John McCamant, Medical Technology Stock Letter  (3/15/13)
"Sound sector and company fundamentals are intact, and improving in some cases. The industry gatekeeper—the U.S. Food and Drug Administration (FDA)—continues to be cooperative. The bullish stock market also bodes well—as cash flows into healthcare funds remain abundant—driving many stocks to what appear to be extended levels." More >

The Stem Cell Revolution Can Jump-Start Your Portfolio: Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (3/14/13)
No single solution will emerge from the growing realm of stem cell technology and regenerative medicine. Instead, multiple innovations will succeed in a field that promises to forever change the practice of medicine—innovations generated by the recognition that living cells are capable of performing a platform of functions that present-day drugs simply cannot. In this Life Sciences Report interview, Jason Kolbert, senior vice president and biotechnology analyst with Maxim Group, provides a detailed analysis of the industry and names companies that investors should be aware of now, while valuations are remarkably low. More >

This Healthcare Fund Is Up 70%: Why I'm Not Selling
Source: Steve Sjuggerud, Steve Sjuggerud's Daily Wealth  (3/12/13)
"Have your exit plan in place, but don't sell. As I've explained many times, this market has the potential to run much higher." More >

10 Biotech Stocks Poised to Run: George Zavoico
Source: George S. Mack of The Life Sciences Report  (3/7/13)
For the first time in ages, conditions for biotech investment are just right. The capital markets have loosened up, and institutional investors are ready to bid up share prices on stories that have both merit and looming catalysts. Sure, there's risk. . .but without it, there's no upside. In this Life Sciences Report interview, Senior Analyst and Managing Director George Zavoico of MLV & Co. identifies a group of biotech companies with market-moving events on their calendars. Sharpen your pencils: From cancer to coronary artery disease to vaccine technology, Zavoico names potential winners.
More >

PDUFA? What's a PDUFA? Understanding the Drug Development Process Is Key to Biotech Investing
Source: George S. Mack of The Life Sciences Report   (3/1/13)
The catalyst theory of investing in biotech stocks is all about the events that move shares in the public markets. Nobody wants dead money sitting in an account, but that's what you might be the case if you don't have a clear view of upcoming events that could make a stock jump in value. More >

Investment-Based Crowdfunding for Biotech Companies: A Revolution with Risk
Source: Krist Werling, Bob Cohen and Michael Pilo, Genetic Engineering & Biotechnology News  (3/1/13)
"The second model is an equity-based or investment-based model and involves an actual investment in an entity that is pursuing a project. Members of the "crowd" that provide funding receive an ownership interest in the entity." More >

Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen
Source: George S. Mack of The Life Sciences Report  (2/28/13)
Gil Van Bokkelen has been in the stem cell industry for more than a decade. In recent years, the co-founder, chairman and chief executive officer of Athersys Inc. has stepped into regenerative medicine’s forefront, acting as a spokesman for the industry as well as demonstrating his love of science and passionately advocating for patients. In this interview with The Life Sciences Report, Van Bokkelen explores the past, present and future of the cell therapy and regenerative medicine industry, and outlines the investment possibilities in small companies on the sector's cutting edge. More >

What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic
Source: George S. Mack of The Life Sciences Report  (2/21/13)
Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation. More >

Why Does the Pentagon Want to Use This Penny Stock to Cure the Flu?
Source: Michael Robinson, Money Morning  (2/21/13)
"Fighting the flu is a big part of the roughly $30B vaccine industry. It's a battle that puts roughly 200,000 Americans in the hospital each year." More >

Like Peanut Butter and Chocolate: RNA Interference's Hot Partnership with Stem Cells
Source: Severine Kirchner, The Daily Reckoning  (2/19/13)
"Combining stem cell treatments with RNAi, the hottest technique in molecular biology, opens more possibilities and hopes than ever before of curing degenerative diseases." More >

Ram Selvaraju: Fall in Love with These Nine Biotech Stocks
Source: George S. Mack of The Life Sciences Report   (2/14/13)
When it comes to unearthing dynamic micro-cap biotech investment opportunities, Ram Selvaraju is a master. Selvaraju, managing director and head of healthcare equity research at Aegis Capital Corp., has selected nine names destined to attract investors willing to take calculated risks, which he shares in this interview with The Life Sciences Report. He also explains why he expects 2013 will be another good year for the biotech industry. More >

Big Growth Stories in Biotech
Source: George S. Mack of The Life Sciences Report  (2/14/13)
Bacteria are pure survivalists, and over billions of years they have evolved to produce ever-newer chemicals to protect themselves against other bugs. In the last 100 years they have begun to protect themselves against the antibiotics that humans have developed from those same bugs. But guess who's winning. In September 2012, the FDA said that more than 70% of the bacteria that produce hospital-associated infections (HAIs) are now resistant to at least one type of antibiotic—and in the year 2000 alone, almost 2 million (2M) cases of HAIs caused close to 99,000 deaths. Too bad the agency didn't give an updated number, because it's a certainty that things are not getting better. Unless a sustainable system is developed to counteract this tide, a catastrophe is just a matter of when, and not if. With not even a tiny bit of exaggeration, the appearance of a devastating superbug is a looming global crisis. More >

Obama's Call for R&D Investment May Boost Medical Research Budgets and Job Markets
Source: Genetic Engineering and Biotechnology News  (2/13/13)
"'If we want to make the best products, we also have to invest in the best ideas,' Obama contended." More >

Biotech May Be on a Roll, but Investors Still Need Innovation, Predictability
Source: Jennifer Boggs, BioWorld  (2/11/13)
"The past several years have seen investment enthusiasm move away from the supposedly risk-reduced reformulation-of-an-existing/generic-drug model. Innovation—new mechanisms, new targets—are what's going to attract the interest and the money." More >

Eight Biotech Growth Names: Greg Wade
Source: George S. Mack of The Life Sciences Report  (2/7/13)
The driving principle behind successful biotech investment for Managing Director and Senior Analyst Greg Wade of Wedbush Securities is to find companies with clinical assets that are of value to patients and hence to the marketplace. In this interview with The Life Sciences Report, Wade offers compelling cases for eight important names that span the market cap gamut. More >

Harry Dent: Roller Coasters, Megaphones, Addictions and Comas—What Kind of Economy Is This?
Source: JT Long of The Gold Report  (2/1/13)
"If I am right, and stocks crash again in late 2014 or early 2015, I want to buy in the healthcare sector in the U.S. and Europe, especially the most leveraged areas: biotech, medical devices and pharmaceuticals. The baby boomers will continue spending on healthcare and healthcare products, even as budgets get crimped by entitlement reductions." More >

Analysts' Watchlist 2013
Source: George S. Mack of The Life Sciences Report  (1/31/13)
More >

The Life Sciences Report Watchlist 2013
Source: George S. Mack of The Life Sciences Report   (1/31/13)
Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months. More >

The Life Sciences Report Watchlist 2013: The FDA and Stock Volatility
Source: George S. Mack of The Life Sciences Report  (1/31/13)
Various steps in the U.S. Food and Drug Adminstration's (FDA) oversight of drug development and approval provide investment opportunity. This brief overview, supplemental to the groundbreaking Life Sciences Report Watchlist 2013, provides insight into FDA events that typically cause movement in a drug company's stock. More >

Is This Drug the Key to an Alzheimer's Cure. . .and Profits?
Source: Michael Robinson, Money Morning  (1/30/13)
"This bit of breakthrough research could supercharge the race for the cure. There's even a way for you to invest." More >

Safest Way to Play Biotech
Source: Kevin Cook, Zacks Investment Research  (1/25/13)
For every company that hits the jackpot with a new marketable drug that makes it through the FDA gauntlets, there are a dozen stocks that run up on such hopes and then crash and burn when the trials fail. More >

Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured
Source: George S. Mack of The Life Sciences Report  (1/24/13)
Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider. More >